^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSH3 mutation

    i
    Entrez ID:
    4437
    Related biomarkers:
    Expression
    Apply
    GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study (NCT03751761)
    Phase 1/2
    Asan Medical Center
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    06/11/2018
    Primary completion :
    08/30/2023
    Completion :
    08/30/2023
    PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation
    |
    Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)